Anti-metastatic effect of curcumin analog pentagamaboronon-0-fructose (PGB-0-F) against 4T1 breast cancer cells

https://doi.org/10.22146/ijbiotech.36431

Yogi Ertanto(1), Rohmad Yudi Utomo(2), Riris Istighfari Jenie(3), Ratna Asmah Susidarti(4), Edy Meiyanto(5*)

(1) Biotechnology Program, Graduate School of Universitas Gadjah Mada, Jalan Teknika Utara, Sleman, Yogyakarta 55281, Indonesia; Army Medical Center, Jalan Mayjen Soetoyo, Cililitan, Jakarta 13640, Indonesia
(2) Cancer Chemoprevention Research Center, Faculty of Pharmacy, Universitas Gadjah Mada, Jalan Sekip Utara, Yogyakarta 55281, Indonesia
(3) Cancer Chemoprevention Research Center, Faculty of Pharmacy, Universitas Gadjah Mada, Jalan Sekip Utara, Yogyakarta 55281, Indonesia; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universitas Gadjah Mada, Jalan Sekip Utara, Yogyakarta 55281, Indonesia
(4) Cancer Chemoprevention Research Center, Faculty of Pharmacy, Universitas Gadjah Mada, Jalan Sekip Utara, Yogyakarta 55281, Indonesia; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universitas Gadjah Mada, Jalan Sekip Utara, Yogyakarta 55281, Indonesia
(5) Cancer Chemoprevention Research Center, Faculty of Pharmacy, Universitas Gadjah Mada, Jalan Sekip Utara, Yogyakarta 55281, Indonesia; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universitas Gadjah Mada, Jalan Sekip Utara, Yogyakarta 55281, Indonesia
(*) Corresponding Author

Abstract


Development of a chemotherapeutic agent and boron carrying pharmaceutical based on triple-negative breast cancer is important due to its metastatic progression. Metastases are often more dangerous than the primary tumor and they are responsible for 90% of all cancer deaths. The purpose of this study was to explore the anti-metastatic activities of the PGB-0 complex with fructose (PGB-0-F) against 4T1 breast cancer cells. A scratch wound healing assay was carried out to determine the migration inhibition ability of PGB-0-F, while MMP-9 expression was analysed using gelatin zymography. The testing of anti-migration activity showed that PGB-0-F inhibited in 4T1 cells, whereas the gelatin zymography assay revealed a suppression of MMP-9 expression. PGB-0-F inhibited closure on 4T1 metastatic breast cancer cells line compared with the control. PGB-0-F decreased the MMP-9 expression level compared with the control. Based on these results, PGB-0-F has the potential to be developed as a chemotherapeutic agent, and especially as an anti-metastatic agent.


Keywords


curcumin analogue, PGB-0-F, 4T1 Cells, migration, MMP-9

Full Text:

PDF


References

Amalina ND, Nurhayati IP, Meiyanto E. 2017. Doxorubicin induces lamellipodia formation and cell migration. Indones J Cancer Chemoprev. 8(2):61–67. doi: 10.14499/indonesianjcanchemoprev8iss2pp61-67.

Bandyopadhyay A, Wang L, Agyin J, Tang Y, Lin S, Yeh IT, De K, Sun LZ. 2010. Doxorubicin in combination with a small TGFβ inhibitor: a potential novel therapy for metastatic breast cancer in mouse models. PLoS ONE. 5(4):e10365. doi:10.1371/journal.pone. 0010365.

Bradke TM, Hall C, Carper SW, Plopper GE. 2008. Phenylboronic acid selectively inhibits human prostate and breast cancer cell migration and decreases viability. Cell Adhes Migr. 2(3):153–160. doi:10.4161/cam.2.3.6484.

Cao J, Han Z, Tian L, Chen K, Fan Y, Ye B, Huang W, Wang C, Huang Z. 2014. Curcumin inhibits EMMPRIN and MMP-9 expression through AMPK-MAPK and PKC signaling in PMA induced macrophages. J Transl Med. 12(1):266. doi:10.1186/ s12967-014-0266-2.

Da’i M, Suhendi A, Meiyanto E, Jenie UA, Kawaichi M. 2017. Apoptosis induction effect of curcumin and its analogs pentagamavunon-0 and pentagamavunon -1 on cancer cell lines. Asian J Pharm Clin Res. 10(3):373–376. doi:10.22159/ajpcr.2017.v10i3. 16311.

DuPré SA, Redelman D, Hunter Jr KW. 2007. The mouse mammary carcinoma 4T1: characterization of the cellular landscape of primary tumours and metastatic tumour foci. Int J Exp Pathol. 88(5):351–360. doi: 10.1111/j.1365-2613.2007.00539.x.

Heppner GH, Miller FR, Shekhar PM. 2000. Nontransgenic models of breast cancer. Breast Cancer Res. 2(5):331. doi:10.1186/bcr77.

Larasati YA, Yoneda-Kato N, Nakamae I, Yokoyama T, Meiyanto E, Kato Jy. 2018. Curcumin targets multiple enzymes involved in the ROS metabolic pathway to suppress tumor cell growth. Sci Rep. 8(1):2039. doi: 10.1038/s41598-018-20179-6.

McAuley EM, Bradke TA, Plopper GE. 2011. Phenylboronic acid is a more potent inhibitor than boric acid of key signaling networks involved in cancer cell migration. Cell Adhes Migr. 5(5):382–386. doi:10.4161/ cam.5.5.18162.

Meiyanto E, Putri D, Susidarti RA, Murwanti R, Sardjiman FA, Husnaa U, Purnomo H, Kawaichi M. 2014. Curcumin and its analogues (PGV-0 and PGV-1) enhance sensitivity of resistant MCF-7 cells to doxorubicin through inhibition of HER2 and NF-kB activation. Asian Pac J Cancer Prev. 15(1):179–184. doi: 10.7314/apjcp.2014.15.1.179.

Moirangthem A, Bondhopadhyay B, Mukherjee M, Bandyopadhyay A, Mukherjee N, Konar K, Bhattacharya S, Basu A. 2016. Simultaneous knockdown of upa and mmp9 can reduce breast cancer progression by increasing cell-cell adhesion and modulating emt genes. Scientific reports. 6:21903. doi:10.1038/ srep21903.

Putri H, Jenie RI, Handayani S, Kastian RF, Meiyanto E. 2016. Combination of potassium pentagamavunon0 and doxorubicin induces apoptosis and cell cycle arrest and inhibits metastasis in breast cancer cells. Asian Pac J Cancer Prev. 17(5):2683–2688.

Reunanen N, Kähäri V. 2013. Matrix metalloproteinases in cancer cell invasion. Austin [TX]: Landes Bioscience.

Song J, Su H, Zhou YY, Guo LL. 2013. Prognostic value of matrix metalloproteinase 9 expression in breast cancer patients: a meta-analysis. Asian Pac J Cancer Prev. 14(3):1615–1621. doi:10.7314/apjcp.2013.14.3.1615.

Utomo RY, Putri H, Pudjono P, Susidarti RA, Jenie RI, Meiyanto E. 2017. Synthesis and cytotoxic activity of 2, 5-bis (4-boronic acid) benzylidine cyclopentanone on HER2 overexpressed-cancer cells. Indones J Pharm. 28(2):74. doi:10.14499/ indonesianjpharm28iss2pp74.

Vandooren J, Van den Steen PE, Opdenakker G. 2013. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. Crit Rev Biochem Mol Biol. 48(3):222–272. doi:10.3109/10409238.2013.770819.

Wallace KB. 2003. Doxorubicin-induced cardiac mitochondrionopathy. Pharmacol Toxicol. 93(3):105–115. doi:10.1034/j.1600-0773.2003.930301.x.

Yoshino K, Suzuki A, Mori Y, Kakihana H, Honda C, Mishima Y, Kobayashi T, Kanda K. 1989. Improvement of solubility of p-boronophenylalanine by complex formation with monosaccharides. Strahlenther Onkol. 165(2-3):127–129.



DOI: https://doi.org/10.22146/ijbiotech.36431

Article Metrics

Abstract views : 1298 | views : 788

Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 The Author(s)

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.